Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Eric R.E. van Thiel"'
Autor:
Milou A.M. Stals, Fleur H.J. Kaptein, Remy H.H. Bemelmans, Thomas van Bemmel, Inge C. Boukema, Dionne C.W. Braeken, Sander J.E. Braken, Carlinda Bresser, Hugo ten Cate, Duco D. Deenstra, Yordi P.A. van Dooren, Laura M. Faber, Marco J.J.H. Grootenboers, Lianne R. de Haan, Carolien Haazer, Antonio Iglesias del Sol, Sarah Kelliher, Ted Koster, Lucia J.M. Kroft, Rick I. Meijer, Fleur Pals, Eric R.E. van Thiel, Peter E. Westerweel, Marije ten Wolde, Frederikus A. Klok, Menno V. Huisman
Publikováno v:
TH Open, Vol 05, Iss 03, Pp e387-e399 (2021)
Background Diagnostic strategies for suspected pulmonary embolism (PE) have not been prospectively evaluated in COVID-19 patients. Methods Prospective, multicenter, outcome study in 707 patients with both (suspected) COVID-19 and suspected PE in 14 h
Externí odkaz:
https://doaj.org/article/9b78aa0cd2dd41b19e1a7f219dce9e3a
Autor:
G.D. Marijn Veerman, Daan P. Hurkmans, Marthe S. Paats, Esther Oomen-de Hoop, Cor H. van der Leest, Eric R.E. van Thiel, Joachim G.J.V. Aerts, Roelof W. van Leeuwen, Anne-Marie C. Dingemans, Ron H.J. Mathijssen
Publikováno v:
Biomedicine and Pharmacotherapy, 155:113695. Elsevier Masson
Afatinib is an oral small-molecule kinase inhibitor (SMKI) approved for treatment of metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) driver mutation. Although oral administration is convenient, most SMKIs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d5e235dc4931fdbeeb62aeaa4cc6504
https://doi.org/10.1016/j.biopha.2022.113695
https://doi.org/10.1016/j.biopha.2022.113695
Autor:
Magdolen Youssef El Soud, Erik M von Meyenfeldt, Eric R.E. van Thiel, Nicky Rademakers, Frank J C van den Broek, Charlotte Johanna Laura Molenaar, Carlijn Tini Ireen de Betue, Geertruid M H Marres, Goof Schep, Gerrit D. Slooter, Sanne Charlotte Hoornweg
BackgroundThe preoperative period can be used to enhance a patient’s functional capacity with multimodal prehabilitation and, consequently improve and fasten postoperative recovery. Especially non-small cell lung cancer (NSCLC) surgical patients ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3526faba040cca0e2a5475275b47c880
https://doi.org/10.21203/rs.3.rs-57399/v1
https://doi.org/10.21203/rs.3.rs-57399/v1
Autor:
Wilhelmina H. Schreurs, Erik M von Meyenfeldt, Rosaline van den Berg, Eric R.E. van Thiel, Geertruid M H Marres, Carlijn Tini Ireen de Betue
Publikováno v:
Seminars in thoracic and cardiovascular surgery. 32(4)
This study aimed to describe perioperative care after anatomical lung resection in the Netherlands, before publication of Enhanced Recovery After Surgery/European Society of Thoracic Surgeons (ERAS/ESTS) guidelines in 2019. An online survey was sent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa454cfefec1a3a1a7c596784488b092
https://pubmed.ncbi.nlm.nih.gov/32610203
https://pubmed.ncbi.nlm.nih.gov/32610203
Publikováno v:
European Journal of Cardio-Thoracic Surgery. 54:560-564
Objectives Length of stay (LOS) in the hospital after lung cancer surgery is influenced by patient characteristics, tumour characteristics, surgical technique and perioperative care. Our objective was to determine whether there were variation in LOS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6efaec8ee9ff3bb0bd6a1bb7c2fc54f9
https://doi.org/10.1093/ejcts/ezy074
https://doi.org/10.1093/ejcts/ezy074
Autor:
Perla J Marang-van de Mheen, Erik M von Meyenfeldt, Hermien Schreurs, Fieke Hoeijmakers, Eric R.E. van Thiel, Elske Marra, Geertruid M H Marres
Publikováno v:
European Journal of Cardio-Thoracic Surgery, 57(4), 747-753. OXFORD UNIV PRESS INC
OBJECTIVES Good perioperative care is aimed at rapid recovery, without complications or readmissions. Length of stay (LOS) is influenced not only by perioperative care routines but also by patient factors, tumour factors, treatment characteristics an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cf65c75143fce81f675662eaf2015b0
https://pubmed.ncbi.nlm.nih.gov/31682265
https://pubmed.ncbi.nlm.nih.gov/31682265
Publikováno v:
Frontiers in Oncology, Vol 1 (2011)
Frontiers in Oncology
FRONTIERS IN ONCOLOGY
Frontiers in Oncology
FRONTIERS IN ONCOLOGY
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis. In view of the poor survival benefit from first-line chemotherapy and the lack of subsequent effective treatment options, there is a strong need for the developme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2196f114c4e81ebe95281dcabffe3b9
http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00022/full
http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00022/full